Cocrystal Pharma, Inc.
COCP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $13 | $21 | $1,360 | $28 |
| Gross Profit | -$13 | -$21 | -$1,360 | -$28 |
| % Margin | – | – | – | – |
| R&D Expenses | $954 | $1,122 | $1,360 | $2,037 |
| G&A Expenses | $0 | $986 | $942 | $0 |
| SG&A Expenses | $1,122 | $986 | $981 | $1,165 |
| Sales & Mktg Exp. | $0 | $0 | $39 | $0 |
| Other Operating Expenses | $0 | -$21 | -$1,360 | $0 |
| Operating Expenses | $2,076 | $2,087 | $981 | $3,202 |
| Operating Income | -$2,089 | -$2,108 | -$2,341 | -$3,230 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $40 | $53 | $40 | -$36 |
| Pre-Tax Income | -$2,049 | -$2,055 | -$2,301 | -$3,266 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,049 | -$2,055 | -$2,301 | -$3,266 |
| % Margin | – | – | – | – |
| EPS | -0.19 | -0.2 | -0.23 | -0.32 |
| % Growth | 5% | 13% | 28.1% | – |
| EPS Diluted | -0.19 | -0.2 | -0.23 | -0.32 |
| Weighted Avg Shares Out | 10,991 | 10,174 | 10,174 | 10,174 |
| Weighted Avg Shares Out Dil | 10,991 | 10,174 | 10,174 | 10,174 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22 | $28 | $37 | $55 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $13 | $21 | $25 | $28 |
| EBITDA | -$2,036 | -$2,087 | -$2,316 | -$3,238 |
| % Margin | – | – | – | – |